High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C (Part 1)
Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus belonging to the Flaviviridae family. Fifty per cent to 80% of people infected develop a chronic infection. A proportion of patients ultimately develop cirrhosis and hepatocellular carcinoma. The lifetime risk of cirrhosis in an HCV carrier is about 20% but may be higher depending on the presence of risk factors recognized to promote fibrosis. The rate of development of liver failure in patients with cirrhosis due to HCV ranges from 25% at five years to 25% at 10 years.
Treatment of HCV to date has involved the use of interferons (IFNs), which have both immunomodulatory and antiviral properties. Standard IFN alpha monotherapy results in a sustained virological response ranging from 6% to 25%, depending on both the dose and the duration of therapy, and the viral and host factors. The addition of the nucleoside analogue ribavirin to standard IFN alpha-2b improves the overall sustained virological response to 43%, and this combination of therapy has been the standard of care. Recent data indicate that long acting pegylated IFNs in combination with ribavirin have an overall sustained virological response of 54% to 56% when given to treatment-naive patients. There are no published data on the efficacy of pegylated IFN and ribavirin in prior nonresponders to IFN alpha-2b and ribavirin. You can finally enjoy safe online shopping for levitra super active plus with the pharmacy you can fully trust no matter if you need a small amount of this medicine or would like to purchase it in bulk not to have to think about it for a long time.